116 related articles for article (PubMed ID: 34082871)
1. Live
Tawfik M; Hadlak S; Götze C; Sokolov M; Kulikov P; Kuskov A; Shtilman M; Sabel BA; Henrich-Noack P
J Biomed Nanotechnol; 2021 May; 17(5):846-858. PubMed ID: 34082871
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Amphiphilic Poly-
Berdiaki A; Perisynaki E; Stratidakis A; Kulikov PP; Kuskov AN; Stivaktakis P; Henrich-Noack P; Luss AL; Shtilman MM; Tzanakakis GN; Tsatsakis A; Nikitovic D
Mol Pharm; 2020 Nov; 17(11):4212-4225. PubMed ID: 32986447
[TBL] [Abstract][Full Text] [Related]
3. Major effects on blood-retina barrier passage by minor alterations in design of polybutylcyanoacrylate nanoparticles.
You Q; Hopf T; Hintz W; Rannabauer S; Voigt N; van Wachem B; Henrich-Noack P; Sabel BA
J Drug Target; 2019 Mar; 27(3):338-346. PubMed ID: 30280953
[TBL] [Abstract][Full Text] [Related]
4. In vitro blood compatibility and in vitro cytotoxicity of amphiphilic poly-N-vinylpyrrolidone nanoparticles.
Tsatsakis A; Stratidakis AK; Goryachaya AV; Tzatzarakis MN; Stivaktakis PD; Docea AO; Berdiaki A; Nikitovic D; Velonia K; Shtilman MI; Rizos AK; Kuskov AN
Food Chem Toxicol; 2019 May; 127():42-52. PubMed ID: 30836108
[TBL] [Abstract][Full Text] [Related]
5. How Nanoparticle Physicochemical Parameters Affect Drug Delivery to Cells in the Retina via Systemic Interactions.
You Q; Sokolov M; Grigartzik L; Hintz W; van Wachem BGM; Henrich-Noack P; Sabel BA
Mol Pharm; 2019 Dec; 16(12):5068-5075. PubMed ID: 31609624
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of amphiphilic poly-N-vinylpyrrolidone nanoparticles containing indomethacin.
Kuskov AN; Voskresenskaya AA; Goryachaya AV; Artyukhov AA; Shtilman MI; Tsatsakis AM
J Mater Sci Mater Med; 2010 May; 21(5):1521-30. PubMed ID: 20177741
[TBL] [Abstract][Full Text] [Related]
7. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles.
Voigt N; Henrich-Noack P; Kockentiedt S; Hintz W; Tomas J; Sabel BA
Eur J Pharm Biopharm; 2014 May; 87(1):19-29. PubMed ID: 24607790
[TBL] [Abstract][Full Text] [Related]
8. Exploring the systemic delivery of a poorly water-soluble model drug to the retina using PLGA nanoparticles.
Zhang E; Osipova N; Sokolov M; Maksimenko O; Semyonkin A; Wang M; Grigartzik L; Gelperina S; Sabel BA; Henrich-Noack P
Eur J Pharm Sci; 2021 Sep; 164():105905. PubMed ID: 34116175
[TBL] [Abstract][Full Text] [Related]
9. Release kinetics of fluorescent dyes from PLGA nanoparticles in retinal blood vessels: In vivo monitoring and ex vivo localization.
Zhang E; Zhukova V; Semyonkin A; Osipova N; Malinovskaya Y; Maksimenko O; Chernikov V; Sokolov M; Grigartzik L; Sabel BA; Gelperina S; Henrich-Noack P
Eur J Pharm Biopharm; 2020 May; 150():131-142. PubMed ID: 32151727
[TBL] [Abstract][Full Text] [Related]
10. Amphiphilic Poly(
Yagolovich A; Kuskov A; Kulikov P; Kurbanova L; Bagrov D; Artykov A; Gasparian M; Sizova S; Oleinikov V; Gileva A; Kirpichnikov M; Dolgikh D; Markvicheva E
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575490
[TBL] [Abstract][Full Text] [Related]
11. Functionalized PLGA nanoparticles prepared by nano-emulsion templating interact selectively with proteins involved in the transport through the blood-brain barrier.
Monge M; Fornaguera C; Quero C; Dols-Perez A; Calderó G; Grijalvo S; García-Celma MJ; Rodríguez-Abreu C; Solans C
Eur J Pharm Biopharm; 2020 Nov; 156():155-164. PubMed ID: 32927077
[TBL] [Abstract][Full Text] [Related]
12. In vivo visualisation of nanoparticle entry into central nervous system tissue.
Henrich-Noack P; Prilloff S; Voigt N; Jin J; Hintz W; Tomas J; Sabel BA
Arch Toxicol; 2012 Jul; 86(7):1099-105. PubMed ID: 22422342
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the Uptake Efficiency and Cytotoxicity of Tetrandrine-Loaded Poly(N-vinylpyrrolidone)-Block-Poly(ε-caprolactone) (PVP-b-PCL) Nanoparticles in the A549 Lung Adenocarcinoma Cell Line.
Xu H; Li X; Kong H; Zeng X; Jin Y; Qi Y; Wang H; Xie W
J Biomed Nanotechnol; 2016 Aug; 12(8):1699-707. PubMed ID: 29342348
[TBL] [Abstract][Full Text] [Related]
14. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA
Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682
[TBL] [Abstract][Full Text] [Related]
15. Ultrabright Fluorescent Polymeric Nanoparticles with a Stealth Pluronic Shell for Live Tracking in the Mouse Brain.
Khalin I; Heimburger D; Melnychuk N; Collot M; Groschup B; Hellal F; Reisch A; Plesnila N; Klymchenko AS
ACS Nano; 2020 Aug; 14(8):9755-9770. PubMed ID: 32680421
[TBL] [Abstract][Full Text] [Related]
16. Folate Receptor α-Modified Nanoparticles for Targeting of the Central Nervous System.
Kuplennik N; Lang K; Steinfeld R; Sosnik A
ACS Appl Mater Interfaces; 2019 Oct; 11(43):39633-39647. PubMed ID: 31532618
[TBL] [Abstract][Full Text] [Related]
17. Amphiphilic poly-N-vynilpyrrolidone nanoparticles: Cytotoxicity and acute toxicity study.
Kuskov AN; Kulikov PP; Shtilman MI; Rakitskii VN; Tsatsakis AM
Food Chem Toxicol; 2016 Oct; 96():273-9. PubMed ID: 27539747
[TBL] [Abstract][Full Text] [Related]
18. The first step into the brain: uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation.
Weiss CK; Kohnle MV; Landfester K; Hauk T; Fischer D; Schmitz-Wienke J; Mailänder V
ChemMedChem; 2008 Sep; 3(9):1395-403. PubMed ID: 18613205
[TBL] [Abstract][Full Text] [Related]
19. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Bortot B; Ruozi B; Dolcetta D; Vandelli MA; Forni F; Severini GM
Curr Med Chem; 2013; 20(17):2212-25. PubMed ID: 23458620
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol-PEG comodified poly (N-butyl) cyanoacrylate nanoparticles for brain delivery: in vitro and in vivo evaluations.
Hu X; Yang F; Liao Y; Li L; Zhang L
Drug Deliv; 2017 Nov; 24(1):121-132. PubMed ID: 28156159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
